OBJECTIVE: To standardize the adjuvant drugs and strengthen the rational application of adjuvant drugs. METHODS: Since Jul. 2018

the clinical pharmacists and the medical department had jointly participated into the control of adjuvant drugs in Anhui Provincial Children’s Hospital（ hereinafter referred to as “our hospital”）. The application data of adjuvant drugs in children from our hospital from the third quarter of 2018 to the second quarter of2019 after intervention were retrospectively analyzed. RESULTS: Through diversity control intervention

the proportion of consumption sum of adjuvant drugs in total consumption sum of drugs in our hospital decreased

from 11. 49%（ 7 402 133. 19 yuan/64 396 414. 32 yuan） in the third quarter of 2018 to 6. 50%（ 4 530 593. 23 yuan/69 751 165. 47 yuan） in the second quarter of 2019. The proportion of consumption sum of neurotrophic drugs in total consumption sum of drugs decreased significantly

from 6. 77%（ 4 356 664. 72 yuan/64 396 414. 32 yuan） in the third quarter of 2018 to4. 38%（ 3 053 004. 97 yuan/69 751 165. 47 yuan） in the second quarter of 2019. The proportion of consumption sum of other drugs in total consumption sum of drugs fluctuated slightly and showed the general decreasing trend. The defined daily dose system of cerebroprotein hydrolysate oral solution was the highest

yet there was no concentration phenomenon. Daily drug cost（ DDC） was calculated according to the defined daily dose（ DDD） for adults

oxiracetam injection had the highest DDC. DDC was calculated according to the DDD of children in our hospital

and the DDC of creatine phosphate sodium for injection was the highest. CONCLUSIONS: After diversity control

the consumption sum of adjuvant drugs in our hospital is in a significant decreasing tendency

and the fluctuation of various medication data is relatively consistent

yet further control of individual varieties is still needed.